Scarica l'app Stockscreener
3.0239
1.30%
-0.0561
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Altimmune Inc Borsa (ALT) Ultime notizie
Altimmune: Pemvidutide AUD Data Due Q3 Makes For Intriguing CatalystUpgrade (ALT) - Seeking Alpha
Here's why you should add Altimmune stock to your portfolio now - MSN
Leerink Sees Altimmune (ALT) As An Attractive Play In The MASH Therapeutics Market - Yahoo Finance
5 Overlooked Penny Stocks to Buy Right Now - Insider Monkey
ETFs Investing in Altimmune, Inc. Stocks - TradingView
ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside? - Stocktwits
ALT Stock Drops Pre-Market On Dilution Fears – Retail Calls It A ‘Horror Story’ - Stocktwits
VKTX Stock Outpaces LLY, ALT Ahead Of Earnings – Retail Eyes Breakout Ahead - Stocktwits
Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
Altimmune, Inc.(NasdaqGM: ALT) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Altimmune, Inc.(NasdaqGM: ALT) added to Russell 2000 Value Benchmark - marketscreener.com
Altimmune, Inc.(NasdaqGM: ALT) added to Russell Microcap Value Benchmark Index - marketscreener.com
Altimmune, Inc.(NasdaqGM: ALT) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Altimmune, Inc.(NasdaqGM: ALT) dropped from Russell 3000E Growth Benchmark - marketscreener.com
ALT STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Annou - The National Law Review
ALT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announce - The National Law Review
LULU, LCID, ALT Stocks Hit 52-Week Lows Today: What's Driving The Selloff? - Stocktwits
ALT Stock Drops On Wider-Than-Expected Q4 Loss: Retail Voices Hopes For Deal To Alleviate Cash Concerns - Stocktwits
Price to book forward of Altimmune, Inc. – NASDAQ:ALT - TradingView
Price to book forward of Altimmune, Inc. – SWB:3G0 - TradingView
Enterprise value to revenue forward of Altimmune, Inc. – NASDAQ:ALT - TradingView
Enterprise value to revenue forward of Altimmune, Inc. – SWB:3G0 - TradingView
Price to sales forward of Altimmune, Inc. – NASDAQ:ALT - TradingView
Price to sales forward of Altimmune, Inc. – SWB:3G0 - TradingView
Price to earnings forward of Altimmune, Inc. – SWB:3G0 - TradingView
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker - The Globe and Mail
Price to earnings forward of Altimmune, Inc. – BMV:ALT1 - TradingView
Price to sales forward of Altimmune, Inc. – BMV:ALT1 - TradingView
Altimmune, Inc. Actuals & Estimates (NASDAQ:ALT) - TradingView
Enterprise value to EBIT forward of Altimmune, Inc. – NASDAQ:ALT - TradingView
Enterprise value to EBIT forward of Altimmune, Inc. – BMV:ALT1 - TradingView
Enterprise value to EBITDA forward of Altimmune, Inc. – NASDAQ:ALT - TradingView
ALT stock guide to pemvidutide's MASH, AUD and ALD setup - MSN
ALT Forecast — Price Target — Prediction for 2027 - TradingView
A2N5Z6 Forecast — Price Target — Prediction for 2027 - TradingView
Is Altimmune, Inc. (ALT) Still a Buy After Price Target Reduction to $20? - Insider Monkey
Is Altimmune worth buying ahead of 2026 catalysts? - MSN
Altimmune Inc (ALT) Valuation: PE, PB & Fair Value Analysis - TradingKey
ALT Initiated Coverage by Leerink PartnersRating Set to Outpe - GuruFocus
Leerink Partners Initiates Altimmune(ALT.US) With Buy Rating, Announces Target Price $10 - Moomoo
Leerink initiates Altimmune stock coverage citing liver drug data By Investing.com - Investing.com South Africa
Leerink initiates Altimmune stock coverage citing liver drug data - Investing.com
Leerink Partners Initiates Altimmune at Outperform With $10 Price Target - marketscreener.com
ALT News | ALTIMMUNE INC (NASDAQ:ALT) - ChartMill
Altimmune Inc (ALT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Why is Altimmune (ALT) down 11.3% since last earnings report? - MSN
Altimmune Inc (ALT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Altimmune Inc (ALT) Institutional Confidence - TradingKey
Altimmune Inc (ALT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Altimmune Inc (ALT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
1.16%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):